Through Noritsu Koki Group’s capital and business alliance with JRM, this theme supports the commercialisation of regenerative medicine products using cardiac resident stem cells, from research and development through manufacturing, regulatory affairs and business development. Development support will continue after the development sponsor for JRM-001 changes.